Book contents
- Frontmatter
- Contents
- Contributors
- Foreword
- Preface
- 1 Introduction
- 2 Genetics of neurocutaneous disorders
- 3 Clinical recognition
- 4 Neurofibromatosis type 1
- 5 Neurofibromatosis type 2
- 6 Tuberous sclerosis complex
- 7 von Hippel–Lindau disease
- 8 Neurocutaneous melanosis
- 9 Nevoid basal cell carcinoma (Gorlin) syndrome
- 10 Epidermal nevus syndromes
- 11 Multiple endocrine neoplasia type 2
- 12 Ataxia–telangiectasia
- 13 Incontinentia pigmenti
- 14 Hypomelanosis of Ito
- 15 Cowden disease
- 16 Pseudoxanthoma elasticum
- 17 Ehlers–Danlos syndromes
- 18 Hutchinson–Gilford progeria syndrome
- 19 Blue rubber bleb nevus syndrome
- 20 Hereditary hemorrhagic telangiectasia (Osler–Weber–Rendu)
- 21 Hereditary neurocutaneous angiomatosis
- 22 Cutaneous hemangiomas: vascular anomaly complex
- 23 Sturge–Weber syndrome
- 24 Lesch–Nyhan syndrome
- 25 Multiple carboxylase deficiency
- 26 Homocystinuria due to cystathionine β-synthase (CBS) deficiency
- 27 Fucosidosis
- 28 Menkes disease
- 29 Xeroderma pigmentosum, Cockayne syndrome and trichothiodystrophy
- 30 Cerebrotendinous xanthomatosis
- 31 Adrenoleukodystrophy
- 32 Peroxisomal disorders
- 33 Familial dysautonomia
- 34 Fabry disease
- 35 Giant axonal neuropathy
- 36 Chediak–Higashi syndrome
- 37 Encephalocraniocutaneous lipomatosis
- 38 Cerebello-trigemino-dermal dysplasia
- 39 Coffin–Siris syndrome: clinical delineation; differential diagnosis and long-term evolution
- 40 Lipoid proteinosis
- 41 Macrodactyly–nerve fibrolipoma
- Index
- References
11 - Multiple endocrine neoplasia type 2
Published online by Cambridge University Press: 31 July 2009
- Frontmatter
- Contents
- Contributors
- Foreword
- Preface
- 1 Introduction
- 2 Genetics of neurocutaneous disorders
- 3 Clinical recognition
- 4 Neurofibromatosis type 1
- 5 Neurofibromatosis type 2
- 6 Tuberous sclerosis complex
- 7 von Hippel–Lindau disease
- 8 Neurocutaneous melanosis
- 9 Nevoid basal cell carcinoma (Gorlin) syndrome
- 10 Epidermal nevus syndromes
- 11 Multiple endocrine neoplasia type 2
- 12 Ataxia–telangiectasia
- 13 Incontinentia pigmenti
- 14 Hypomelanosis of Ito
- 15 Cowden disease
- 16 Pseudoxanthoma elasticum
- 17 Ehlers–Danlos syndromes
- 18 Hutchinson–Gilford progeria syndrome
- 19 Blue rubber bleb nevus syndrome
- 20 Hereditary hemorrhagic telangiectasia (Osler–Weber–Rendu)
- 21 Hereditary neurocutaneous angiomatosis
- 22 Cutaneous hemangiomas: vascular anomaly complex
- 23 Sturge–Weber syndrome
- 24 Lesch–Nyhan syndrome
- 25 Multiple carboxylase deficiency
- 26 Homocystinuria due to cystathionine β-synthase (CBS) deficiency
- 27 Fucosidosis
- 28 Menkes disease
- 29 Xeroderma pigmentosum, Cockayne syndrome and trichothiodystrophy
- 30 Cerebrotendinous xanthomatosis
- 31 Adrenoleukodystrophy
- 32 Peroxisomal disorders
- 33 Familial dysautonomia
- 34 Fabry disease
- 35 Giant axonal neuropathy
- 36 Chediak–Higashi syndrome
- 37 Encephalocraniocutaneous lipomatosis
- 38 Cerebello-trigemino-dermal dysplasia
- 39 Coffin–Siris syndrome: clinical delineation; differential diagnosis and long-term evolution
- 40 Lipoid proteinosis
- 41 Macrodactyly–nerve fibrolipoma
- Index
- References
Summary
Introduction
Multiple endocrine neoplasia Type 2 (MEN-2) is a distinct autosomal dominant inherited tumor syndrome with three recognized clinical subtypes and a common genetic origin from mutation of the RET proto-oncogene. The syndrome was originally identified by Sipple (1961), who reported an association of pheochromocytoma with medullary thyroid carcinoma (MTC). MEN-2A was originally known as Sipple's syndrome – the triad of MTC, pheochromocytoma, and hyperparathyroidism. Wagenmann (1922) and Froboese (1923) initially described the clinical syndrome of mucosal neuromas, and Williams and Pollack (1966) further delineated the MEN-2B phenotype with the description of a syndrome of mucosal neuromas, intestinal ganglioneuromatosis, pheochromocytoma, and MTC.
A great deal has been learned regarding the origins, pathogenesis, and clinical manifestations of the disease since its original descriptions. The isolation of the RET proto-oncogene has revolutionized screening for the disease in affected kindreds as well as the approach to management of the clinical manifestations. The clinical spectrum of MEN-2 is currently defined in the Operational Classification of MEN-2 Disease Phenotype by the International RET Mutation Consortium, summarized in Table 11.1 (Eng et al., 1996). MEN-2A is by far the most common variant, accounting for over 90% of cases of MEN-2. MEN-2B comprises about 5% of cases, and Familial MTC (FMTC) accounts for the remainder (Eng, 1999). Virtually all patients with MEN-2 develop C-cell hyperplasia and/or MTC, and MTC is responsible for a majority of the mortality associated with MEN-2. MEN-2A is also associated with pheochromocytoma in 50% and hyperparathyroidism in 20–30% of patients.
- Type
- Chapter
- Information
- Neurocutaneous Disorders , pp. 105 - 111Publisher: Cambridge University PressPrint publication year: 2004
References
- 1
- Cited by